Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Boehringer Ingelheim
Merck
AstraZeneca
Moodys

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Litigation Details for Pfizer Inc. v. Mylan Inc. (D. Del. 2009)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Pfizer Inc. v. Mylan Inc. (D. Del. 2009)

Docket   Start Trial Date Filed 2009-06-15
Court District Court, D. Delaware Date Terminated 2011-06-30
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand None Referred To
Parties MATRIX LABORATORIES INC.; MATRIX LABORATORIES LIMITED; MYLAN INC.; PFIZER INC.; PFIZER IRELAND PHARMACEUTICALS; WARNER-LAMBERT COMPANY; WARNER-LAMBERT COMPANY LLC
Patents 5,686,104; 5,969,156; 6,126,971
Attorneys Dominick T. Gattuso; Neal C. Belgam; Rudolf E. Hutz; Samuel Taylor Hirzel , II
Link to Docket External link to docket
Small Molecule Drugs cited in Pfizer Inc. v. Mylan Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for Pfizer Inc. v. Mylan Inc. (D. Del. 2009)

Date Filed Document No. Description Snippet Link To Document
2010-09-08 106 2010 Regarding Discovery Relating to U.S. Patent Nos. 5,686,104 and 6,126,971 - filed by Pfizer Inc., Pfizer…2009 30 June 2011 1:09-cv-00441 830 Patent None District Court, D. Delaware External link to document
2010-09-22 116 2010 Regarding Discovery Relating to U.S. Patent Nos. 5,686,104 and 6,126,971 filed by Matrix Laboratories…2009 30 June 2011 1:09-cv-00441 830 Patent None District Court, D. Delaware External link to document
2010-09-23 118 2010 Regarding Discovery Relating to U.S. Patent Nos. 5,686,104 and 6,126,971 - filed by Pfizer Inc., Pfizer…2009 30 June 2011 1:09-cv-00441 830 Patent None District Court, D. Delaware External link to document
2010-10-25 144 Construction Brief Regarding U.S. Patent Nos. 5,969,156 and 5,686,104 filed by Pfizer Inc., Pfizer Ireland…2009 30 June 2011 1:09-cv-00441 830 Patent None District Court, D. Delaware External link to document
2010-11-15 162 CONSTRUCTION BRIEF REGARDING U.S. PATENT NOS. 5,969,156 AND 5,686,104) filed by Pfizer Inc., Pfizer Ireland…2009 30 June 2011 1:09-cv-00441 830 Patent None District Court, D. Delaware External link to document
2011-06-30 192 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,969,156; 6,087,511; US 6,274,740…2009 30 June 2011 1:09-cv-00441 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
AstraZeneca
Dow
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.